CymaBay Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
CymaBay Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 206,535,000 | 273,721,000 | 35,482,000 | 59,150,000 | 20,291,000 | 30,691,000 | 52,753,000 | 73,995,000 | 125,806,000 | 68,963 | 32,897,000 | 43,326,000 | 28,193 | 47,273,000 | 96,051,000 | 56,794,000 | 24,869 | 43,462,000 | 28,081,000 | 125,574,000 | 48,995,000 | 41,795,000 | 44,726,000 | 65,581,000 | 23,054,000 | 23,009,000 | 9,509,000 | 13,673,000 | 10,495,000 | 6,821,000 | 12,411,000 | 21,197,000 | 7,706,000 | 6,691,000 | 11,702,000 | 10,841,000 | 11,586,000 | 16,356,000 | 8,002,000 | 22,342,000 | 24,401,000 | 32,080,000 |
| marketable securities | 187,720,000 | 165,057,000 | 178,362,000 | 177,215,000 | 115,194,000 | 122,724,000 | 111,130,000 | 114,564,000 | 60,729,000 | 44,825 | 73,237,000 | 82,132,000 | 118,130 | 113,991,000 | 72,856,000 | 119,438,000 | 166,076 | 175,132,000 | 213,126,000 | 139,182,000 | 129,669,000 | 156,350,000 | 167,353,000 | 163,955,000 | 74,156,000 | 79,160,000 | 7,217,000 | 9,723,000 | 6,499,000 | 16,313,000 | 16,705,000 | 14,057,000 | 33,774,000 | 40,162,000 | 15,329,000 | 21,950,000 | 23,209,000 | 26,270,000 | 15,624,000 | 6,191,000 | 6,843,000 | |
| prepaid expenses and other current assets | 9,547,000 | 8,881,000 | 10,227,000 | 6,355,000 | 2,588,000 | |||||||||||||||||||||||||||||||||||||
| total current assets | 403,802,000 | 447,659,000 | 224,071,000 | 242,720,000 | 138,073,000 | 155,124,000 | 166,611,000 | 192,046,000 | 191,099,000 | 119,576 | 113,813,000 | 133,273,000 | 151,585 | 166,129,000 | 174,102,000 | 185,949,000 | 202,923 | 227,771,000 | 249,813,000 | 270,064,000 | 181,562,000 | 202,255,000 | 216,715,000 | 231,176,000 | 103,544,000 | 103,659,000 | 17,869,000 | 24,557,000 | 18,528,000 | 24,480,000 | 30,164,000 | 36,490,000 | 42,794,000 | 48,573,000 | 28,303,000 | 34,492,000 | 37,229,000 | 44,399,000 | 25,432,000 | 30,933,000 | 32,239,000 | 32,113,000 |
| non-current marketable securities | 21,932,000 | 6,874,000 | 4,885,000 | 8,067,000 | ||||||||||||||||||||||||||||||||||||||
| property and equipment | 465,000 | 453,000 | 626,000 | 729,000 | 701,000 | 845,000 | 993,000 | 1,024,000 | 1,178,000 | 1,341 | 1,511,000 | 1,690,000 | 1,761 | 1,929,000 | 2,075,000 | 2,242,000 | 2,409 | 2,549,000 | 2,693,000 | 2,794,000 | 2,905,000 | 90,000 | 90,000 | 103,000 | 69,000 | 51,000 | 59,000 | 68,000 | 77,000 | 85,000 | 90,000 | 59,000 | 64,000 | 69,000 | 75,000 | 80,000 | 86,000 | 91,000 | 87,000 | 60,000 | 3,000 | 9,000 |
| right-of-use assets | 5,260,000 | |||||||||||||||||||||||||||||||||||||||||
| other assets | 3,227,000 | 2,879,000 | 1,854,000 | 1,733,000 | 2,909,000 | 3,081,000 | 3,026,000 | 2,448,000 | 1,720,000 | 1,721 | 1,447,000 | 1,446,000 | 207 | 160,000 | 160,000 | 160,000 | 160 | 1,261,000 | 730,000 | 1,122,000 | 2,280,000 | 1,363,000 | 1,363,000 | 980,000 | 634,000 | 634,000 | 804,000 | 754,000 | 754,000 | 221,000 | 221,000 | 221,000 | 221,000 | 221,000 | 292,000 | 158,000 | 159,000 | 159,000 | 514,000 | 203,000 | 258,000 | 42,000 |
| total assets | 434,686,000 | 451,048,000 | 226,650,000 | 245,319,000 | 141,852,000 | 159,247,000 | 177,724,000 | 200,642,000 | 202,318,000 | 122,902 | 117,041,000 | 136,682,000 | 153,825 | 168,486,000 | 176,597,000 | 188,600,000 | 205,727 | 231,800,000 | 253,435,000 | 274,157,000 | 186,747,000 | 203,708,000 | 218,168,000 | 232,259,000 | 104,247,000 | 104,344,000 | 18,732,000 | 25,379,000 | 19,359,000 | 24,786,000 | 30,475,000 | 36,770,000 | 43,079,000 | 48,863,000 | 28,670,000 | 34,730,000 | 37,474,000 | 44,649,000 | 26,033,000 | 31,196,000 | 32,500,000 | 32,164,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||||||||
| accounts payable | 3,828,000 | 2,731,000 | 4,589,000 | 1,633,000 | 1,096,000 | 479,000 | 866,000 | 199,000 | 2,728,000 | 764 | 1,050,000 | 1,606,000 | 231 | 947,000 | 476,000 | 1,213,000 | 2,503 | 1,494,000 | 2,882,000 | 2,410,000 | 1,973,000 | 1,629,000 | 1,336,000 | 2,038,000 | 1,311,000 | 1,235,000 | 1,101,000 | 1,096,000 | 899,000 | 935,000 | 1,272,000 | 1,777,000 | 1,008,000 | 707,000 | 1,721,000 | 1,527,000 | 2,085,000 | 1,047,000 | 1,262,000 | 1,069,000 | 697,000 | 1,039,000 |
| accrued research and development expenses | 5,633,000 | 5,835,000 | 4,838,000 | 5,565,000 | 6,530,000 | 6,622,000 | 7,028,000 | 9,659,000 | 9,752,000 | 6,451 | 4,126,000 | 3,294,000 | 4,698 | 5,729,000 | 5,437,000 | 7,351,000 | 9,218 | 10,819,000 | ||||||||||||||||||||||||
| development financing liability - current portion | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||
| deferred collaboration revenue - current portion | 1,689,000 | |||||||||||||||||||||||||||||||||||||||||
| other accrued liabilities | 15,693,000 | 9,468,000 | 6,835,000 | 5,569,000 | 7,815,000 | 5,610,000 | 4,666,000 | 4,181,000 | 5,886,000 | 4,526 | 3,783,000 | 3,009,000 | 4,910 | 3,693,000 | 2,686,000 | 1,641,000 | 2,722 | 5,045,000 | 3,266,000 | 2,782,000 | 3,854,000 | 2,437,000 | 2,071,000 | |||||||||||||||||||
| total current liabilities | 36,843,000 | 19,666,000 | 17,894,000 | 46,500,000 | 15,441,000 | 12,711,000 | 12,560,000 | 14,039,000 | 18,366,000 | 11,741 | 8,959,000 | 7,909,000 | 9,857 | 10,462,000 | 9,478,000 | 11,922,000 | 17,636 | 17,358,000 | 15,422,000 | 14,473,000 | 14,415,000 | 13,640,000 | 16,916,000 | 17,918,000 | 16,310,000 | 14,028,000 | 11,988,000 | 10,780,000 | 9,311,000 | 7,751,000 | 7,542,000 | 6,747,000 | 6,146,000 | 6,153,000 | 8,545,000 | 13,664,000 | 20,459,000 | 15,032,000 | 13,757,000 | 15,521,000 | 9,488,000 | 2,243,000 |
| development financing liability - non-current portion | 99,172,000 | |||||||||||||||||||||||||||||||||||||||||
| deferred collaboration revenue - non-current portion | 1,100,000 | |||||||||||||||||||||||||||||||||||||||||
| lease liabilities - non-current portion | 5,315,000 | |||||||||||||||||||||||||||||||||||||||||
| total liabilities | 142,430,000 | 124,857,000 | 118,242,000 | 141,130,000 | 105,698,000 | 99,069,000 | 95,267,000 | 93,261,000 | 69,381,000 | 35,844 | 9,947,000 | 9,036,000 | 11,119 | 11,851,000 | 10,989,000 | 13,552,000 | 19,379 | 19,209,000 | 17,376,000 | 16,526,000 | 16,329,000 | 15,577,000 | 18,955,000 | 20,060,000 | 19,300,000 | 17,840,000 | 16,593,000 | 16,152,000 | 15,422,000 | 14,574,000 | 15,054,000 | 14,924,000 | 14,964,000 | 15,369,000 | 10,990,000 | 16,462,000 | 23,624,000 | 18,518,000 | 17,556,000 | 19,820,000 | 13,904,000 | 12,058,000 |
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||||||
| common stock | 11,000 | 18,000 | 17,000 | 17,000 | 8,000 | 8,000 | 8,000 | 8,000 | 8,000 | 7 | 7,000 | 7,000 | 7 | 7,000 | 7,000 | 7,000 | 7 | 7,000 | 7,000 | 7,000 | 6,000 | 6,000 | 6,000 | 6,000 | 4,000 | 4,000 | 3,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 |
| additional paid-in capital | 1,270,328,000 | 1,262,560,000 | 1,010,958,000 | 1,005,877,000 | 909,329,000 | 906,968,000 | 904,609,000 | 902,217,000 | 899,798,000 | 827,365 | 824,717,000 | 822,054,000 | 819,549 | 817,653,000 | 815,101,000 | 814,131,000 | 812,133 | 808,866,000 | 806,001,000 | 803,718,000 | 693,534,000 | 691,771,000 | 684,326,000 | 679,846,000 | 535,503,000 | 531,986,000 | 439,376,000 | 437,536,000 | 426,895,000 | 426,219,000 | 425,552,000 | 424,981,000 | 424,422,000 | 423,809,000 | 402,136,000 | 401,361,000 | 394,622,000 | 394,182,000 | 370,552,000 | 370,276,000 | 367,435,000 | 365,033,000 |
| accumulated other comprehensive income | 144,000 | -13,000 | -1 | 1,000 | -6,000 | 8 | 82,000 | 186,000 | -130,000 | 80 | 177,000 | 228,000 | 45,000 | -14,000 | -15,000 | 3,000 | 2,000 | |||||||||||||||||||||||||
| accumulated deficit | -978,227,000 | -936,325,000 | -902,443,000 | -901,635,000 | -872,857,000 | -846,224,000 | -821,719,000 | -794,625,000 | -766,856,000 | -740,313 | -717,631,000 | -694,409,000 | -676,858 | -661,107,000 | -649,686,000 | -638,960,000 | -625,872 | -596,459,000 | -570,177,000 | -546,139,000 | -523,064,000 | -503,615,000 | -485,052,000 | -467,521,000 | -450,516,000 | -445,473,000 | -437,239,000 | -428,310,000 | -422,959,000 | -416,007,000 | -410,128,000 | -403,136,000 | -396,288,000 | -390,309,000 | -384,444,000 | -383,087,000 | -380,759,000 | -368,037,000 | -362,076,000 | -358,904,000 | -348,842,000 | -344,928,000 |
| total stockholders’ equity | 292,256,000 | 326,191,000 | 108,408,000 | 104,189,000 | 36,154,000 | 60,178,000 | 82,457,000 | 107,381,000 | 132,937,000 | 87,058 | 107,094,000 | 127,646,000 | 142,706 | 156,635,000 | 165,608,000 | 175,048,000 | 186,348 | 212,591,000 | 236,059,000 | 257,631,000 | 170,418,000 | 188,131,000 | 199,213,000 | 212,199,000 | 84,947,000 | 86,504,000 | 2,139,000 | 9,227,000 | 3,937,000 | 10,212,000 | 15,421,000 | 21,846,000 | 28,115,000 | 33,494,000 | 17,680,000 | 18,268,000 | 13,850,000 | 26,131,000 | 8,477,000 | 11,376,000 | 18,596,000 | 20,106,000 |
| total liabilities and stockholders’ equity | 434,686,000 | 451,048,000 | 226,650,000 | 245,319,000 | 141,852,000 | 159,247,000 | 177,724,000 | 200,642,000 | 202,318,000 | 122,902 | 117,041,000 | 136,682,000 | 153,825 | 168,486,000 | 176,597,000 | 188,600,000 | 205,727 | 231,800,000 | 253,435,000 | 274,157,000 | 186,747,000 | 203,708,000 | 218,168,000 | 232,259,000 | 104,247,000 | 104,344,000 | 18,732,000 | 25,379,000 | 19,359,000 | 24,786,000 | 30,475,000 | 36,770,000 | 43,079,000 | 48,863,000 | 28,670,000 | 34,730,000 | 37,474,000 | 44,649,000 | 26,033,000 | 31,196,000 | ||
| operating lease right-of-use asset | 57,000 | 99,000 | 137,000 | 169,000 | 197,000 | 220,000 | 239,000 | 254,000 | 264 | 270,000 | 273,000 | 272 | 268,000 | 260,000 | 249,000 | 219,000 | 199,000 | 177,000 | ||||||||||||||||||||||||
| deferred collaboration revenue—current portion | 1,632,000 | 1,632,000 | ||||||||||||||||||||||||||||||||||||||||
| development financing liability | 104,091,000 | 99,248,000 | 94,630,000 | 90,227,000 | 86,152,000 | 82,333,000 | 78,685,000 | 50,320,000 | 23,259 | |||||||||||||||||||||||||||||||||
| deferred collaboration revenue—non-current portion | 1,100,000 | 1,100,000 | ||||||||||||||||||||||||||||||||||||||||
| long-term portion of operating lease liability | 30,000 | 206,000 | 374,000 | 537,000 | 695,000 | 844 | 988,000 | 1,127,000 | 1,262 | 1,389,000 | 1,511,000 | 1,630,000 | 1,743 | 1,851,000 | 1,954,000 | 2,053,000 | ||||||||||||||||||||||||||
| accumulated other comprehensive loss | -62,000 | -124,000 | -70,000 | -326,000 | -574,000 | -441,000 | -219,000 | -58,000 | -31,000 | -67,000 | -132,000 | -44,000 | -13,000 | -1,000 | -2,000 | -1,000 | -2,000 | -5,000 | -1,000 | -21,000 | -8,000 | -13,000 | -7,000 | |||||||||||||||||||
| deferred collaboration revenue | 33,733,000 | |||||||||||||||||||||||||||||||||||||||||
| prepaid research and development expenses | 668,000 | 1,103,000 | 1,384,000 | 2,371,000 | 5,071 | 6,060,000 | 5,631,000 | 2,221 | 3,761,000 | 4,012,000 | 7,922,000 | 9,910 | 7,900,000 | |||||||||||||||||||||||||||||
| other prepaid expenses and current assets | 1,041,000 | 1,625,000 | 2,103,000 | 2,193,000 | 648 | 1,392,000 | 1,919,000 | 2,764 | 820,000 | 974,000 | ||||||||||||||||||||||||||||||||
| accrued interest receivable | 69 | 227,000 | 265,000 | 277 | 284,000 | 209,000 | 377,000 | 687 | 509,000 | 725,000 | 481,000 | 217,000 | 405,000 | 22,000 | 19,000 | 96,000 | 186,000 | 209,000 | 83,000 | 199,000 | 136,000 | 223,000 | 134,000 | 90,000 | 68,000 | |||||||||||||||||
| accrued restructuring | 18 | 93,000 | 879,000 | 1,717,000 | 3,193 | |||||||||||||||||||||||||||||||||||||
| other prepaid expenses | 1,418,000 | 1,381 | 768,000 | |||||||||||||||||||||||||||||||||||||||
| operating lease right-of-use assets | 235 | |||||||||||||||||||||||||||||||||||||||||
| other liabilities | 13,000 | 14,000 | 18,000 | 16,000 | 9,000 | |||||||||||||||||||||||||||||||||||||
| prepaid expenses | 7,881,000 | 4,827,000 | 2,594,000 | 1,793,000 | 2,131,000 | 1,367,000 | 1,208,000 | 1,368,000 | 1,126,000 | 1,128,000 | 1,369,000 | 1,324,000 | 1,029,000 | 1,140,000 | 1,128,000 | 1,491,000 | 996,000 | 1,363,000 | 1,991,000 | 1,402,000 | 1,475,000 | 1,876,000 | 364,000 | 33,000 | ||||||||||||||||||
| accrued clinical trial expenses | 9,274,000 | 9,281,000 | 9,574,000 | 7,877,000 | ||||||||||||||||||||||||||||||||||||||
| receivable from collaboration | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||
| other current assets | 304,000 | 2,100,000 | 2,100,000 | 273,000 | 126,000 | 122,000 | 17,000 | 33,000 | 165,000 | 20,000 | 176,000 | 139,000 | 96,000 | 134,000 | 187,000 | 266,000 | 453,000 | |||||||||||||||||||||||||
| accrued clinical expenses | 8,588,000 | |||||||||||||||||||||||||||||||||||||||||
| warrant liability | 5,632,000 | 7,648,000 | 6,091,000 | 5,862,000 | 4,343,000 | 3,279,000 | 1,145,000 | 1,177,000 | 1,259,000 | 900,000 | 1,220,000 | 1,356,000 | 2,181,000 | 7,704,000 | 13,596,000 | 8,766,000 | 8,888,000 | 11,638,000 | 6,466,000 | |||||||||||||||||||||||
| facility loan | 3,219,000 | 3,108,000 | 3,001,000 | 2,897,000 | 2,797,000 | 2,700,000 | 2,607,000 | 2,041,000 | 1,262,000 | 509,000 | 1,450,000 | 1,403,000 | 1,355,000 | 1,193,000 | 795,000 | 410,000 | 38,000 | |||||||||||||||||||||||||
| accrued interest payable | 37,000 | 43,000 | 49,000 | 55,000 | 60,000 | 66,000 | 72,000 | 73,000 | 73,000 | 73,000 | 73,000 | 29,000 | 32,000 | 35,000 | 36,000 | 36,000 | 36,000 | 36,000 | ||||||||||||||||||||||||
| deferred rent, less current portion | 1,914,000 | |||||||||||||||||||||||||||||||||||||||||
| facility loan, less current portion | 2,142,000 | 2,990,000 | 3,809,000 | 4,599,000 | 5,362,000 | 6,098,000 | 6,809,000 | 7,496,000 | 8,159,000 | 8,799,000 | 9,198,000 | 2,429,000 | 2,784,000 | 3,152,000 | 3,476,000 | 3,793,000 | 4,099,000 | 4,407,000 | ||||||||||||||||||||||||
| deferred rent, net of current portion | 1,937,000 | 2,039,000 | ||||||||||||||||||||||||||||||||||||||||
| accrued liabilities | 4,976,000 | 5,757,000 | 3,881,000 | 3,592,000 | 3,548,000 | 4,501,000 | 2,960,000 | 2,897,000 | 2,735,000 | 3,336,000 | 4,017,000 | 3,164,000 | 2,998,000 | 3,388,000 | 3,990,000 | 2,776,000 | 2,368,000 | 2,251,000 | 1,204,000 | |||||||||||||||||||||||
| other liabilites | 3,000 | 6,000 | 10,000 | 16,000 | 18,000 | 19,000 | 14,000 | 13,000 | 10,000 | 6,000 | 200,000 | |||||||||||||||||||||||||||||||
| contract receivables | 17,000 | 211,000 | 14,000 | 10,000 | 168,000 | 110,000 | ||||||||||||||||||||||||||||||||||||
| liabilities and redeemable convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
| convertible notes | ||||||||||||||||||||||||||||||||||||||||||
| redeemable convertible preferred stock | ||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value: 10,000,000 shares authorized at december 31, 2013; no shares authorized at december 31, 2012; no shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||||||
| total liabilities and redeemable convertible preferred stock and stockholders’ equity | 32,500,000 | 32,164,000 | ||||||||||||||||||||||||||||||||||||||||
| long term warrant liability | 5,310,000 | |||||||||||||||||||||||||||||||||||||||||
| deferred rent | 131,000 | |||||||||||||||||||||||||||||||||||||||||
| stockholders’ deficit: |
We provide you with 20 years of balance sheets for CymaBay Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CymaBay Therapeutics. Explore the full financial landscape of CymaBay Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about CymaBay Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.